Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51250 | 0.94 | KCNH2 (0.56) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL50267 | 0.92 | NR1I2 (0.52) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL642026 | 0.90 | NR1I2 (0.63) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL5377079 | 0.90 | NR1I2 (0.51) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL703081 | 0.90 | KCNH2 (0.58) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL4828013 | 0.89 | NR1I2 (0.68) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL1573220 | 0.89 | SCN9A (0.54) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL11893094 | 0.89 | KCNH2 (0.57) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL13792409 | 0.89 | KCNH2 (0.65) | KCNH2SCN9ANR1I2SCN5ACYP3A4 | |
| SCHEMBL13940997 | 0.89 | NR1I2 (0.58) | KCNH2SCN9ANR1I2SCN5ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518073-B1 | Compounds for the treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2518073-B1 | Compounds for the treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2401280-B1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2118108-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2518073-A1 | Compounds for the treatment of Hepatitis C | Bristol-Myers Squibb Company (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2518073-A1 | Compounds for the treatment of Hepatitis C | Bristol-Myers Squibb Company (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2209784-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2209784-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | KCNH2 934/4885SCN9A 289/4885NR1I2 201/4885 |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KCNH2 3808/4885SCN9A 4595/4885NR1I2 189/4885 |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, OAT | KCNH2 3003/4885SCN9A 3801/4885NR1I2 158/4885 |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KCNH2 3808/4885SCN9A 4595/4885NR1I2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.